Mastering Mood and Anxiety Disorders in Geriatric Patients for the CGP Certified Geriatric Pharmacist Exam

Understanding Mood and Anxiety Disorders in Geriatric Patients for the CGP Exam

As an aspiring or practicing Certified Geriatric Pharmacist, your expertise in managing the complex healthcare needs of older adults is paramount. Among the most prevalent and often challenging conditions encountered are mood and anxiety disorders. These conditions significantly impact the quality of life, functional status, and overall health outcomes for geriatric patients. For the CGP Certified Geriatric Pharmacist exam, a deep understanding of their unique presentation, diagnosis, and management in this population is not just beneficial—it's essential for ensuring patient safety and optimal care.

This section delves into the nuances of mood and anxiety disorders in older adults, equipping you with the knowledge needed to excel on the CGP exam and confidently address these critical issues in practice. We'll explore why these conditions are often missed, the specific pharmacological and non-pharmacological strategies, and how age-related physiological changes dictate treatment approaches as of April 2026.

Key Concepts: Navigating Geriatric Mood and Anxiety

Mood and anxiety disorders affect a significant proportion of older adults, yet they are frequently underdiagnosed and undertreated due to atypical presentations, comorbidity with other medical conditions, and societal stigma. The CGP exam expects you to recognize these challenges and apply appropriate, patient-centered solutions.

Depression in Older Adults

• Prevalence and Impact: Depression affects approximately 1-5% of community-dwelling older adults, but rates are higher in hospitalized (10-12%) and long-term care residents (up to 30%). It's a major risk factor for suicide, functional decline, increased morbidity/mortality, and worsened outcomes for chronic diseases.
• Atypical Presentation: Unlike younger adults, older adults with depression may present with less overt sadness. Common presentations include:
  • Somatic complaints (e.g., unexplained pains, fatigue, gastrointestinal issues).
  • Anhedonia (loss of pleasure in activities previously enjoyed).
  • Cognitive impairment (pseudodementia), which can be mistaken for actual dementia.
  • Social withdrawal, irritability, or increased dependency.
  • Lack of emotional expression (flat affect).
• Risk Factors: Chronic medical illnesses (e.g., stroke, heart disease, diabetes, cancer), functional impairment, social isolation, bereavement, caregiver burden, polypharmacy, and a history of depression are significant risk factors.
• Screening Tools: The Geriatric Depression Scale (GDS-15 or GDS-30) is a widely used and validated screening tool for depression in older adults, particularly those with cognitive impairment.
• Pharmacological Management:
  • First-line: Selective Serotonin Reuptake Inhibitors (SSRIs) such as escitalopram, citalopram, and sertraline are generally preferred due to their favorable side effect profiles compared to older antidepressants.
    • Considerations: Start low, go slow (e.g., half the usual adult starting dose). Monitor for hyponatremia (especially with diuretics), QTc prolongation (especially with citalopram/escitalopram), gastrointestinal upset, and agitation.
    • Avoid paroxetine due to anticholinergic effects and drug interactions.
  • Second-line: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like venlafaxine or duloxetine may be used, particularly if comorbid pain is present. Monitor for blood pressure increases.
  • Other Agents: Mirtazapine can be useful for patients with insomnia and anorexia due to its sedating and appetite-stimulating effects. Bupropion may be considered but has a lower seizure threshold. Tricyclic Antidepressants (TCAs) are generally avoided due to significant anticholinergic and cardiovascular side effects (Beers Criteria).
  • Duration: Treatment should continue for at least 6-12 months after remission of symptoms to prevent relapse.
• Non-pharmacological Management: Psychotherapy (Cognitive Behavioral Therapy - CBT, interpersonal therapy), exercise, social engagement, light therapy, and addressing psychosocial stressors are crucial.

Anxiety Disorders in Older Adults

• Prevalence and Impact: Anxiety disorders are as common, if not more common, than depression in older adults, often co-occurring with depression and chronic medical conditions. They can lead to functional decline, impaired sleep, cognitive difficulties, and increased healthcare utilization.
• Atypical Presentation: Similar to depression, anxiety may present with:
  • Somatic complaints (e.g., shortness of breath, palpitations, dizziness, abdominal discomfort).
  • Exaggerated worry about health, finances, or family.
  • Sleep disturbances.
  • Difficulty concentrating, irritability.
  • Restlessness, agitation.
• Types: Generalized Anxiety Disorder (GAD) is most common, followed by specific phobias, panic disorder, and Post-Traumatic Stress Disorder (PTSD).
• Risk Factors: Chronic medical conditions, functional impairment, cognitive decline, bereavement, and certain medications can exacerbate anxiety.
• Screening Tools: The Generalized Anxiety Disorder 7-item scale (GAD-7) is a common screening tool.
• Pharmacological Management:
  • First-line: SSRIs and SNRIs are also first-line for most anxiety disorders in older adults, given their efficacy and lower risk profile compared to benzodiazepines. Dosing principles are similar to depression (start low, go slow).
  • Benzodiazepines: Generally discouraged for long-term use due to significant risks in older adults, including:
    • Increased risk of falls and fractures.
    • Cognitive impairment, delirium, and worsening dementia.
    • Sedation, motor incoordination.
    • Dependence and withdrawal symptoms.
    • The Beers Criteria strongly recommend avoiding long-acting benzodiazepines and caution against any benzodiazepine use for anxiety in older adults, especially for extended periods. If used, short-acting agents like lorazepam or oxazepam at the lowest effective dose for the shortest duration possible are preferred, but still with caution.
  • Alternatives to Benzodiazepines: Buspirone (non-sedating, takes weeks to work), gabapentin or pregabalin (especially with neuropathic pain), hydroxyzine (antihistamine, sedating, anticholinergic effects), and atypical antipsychotics (for severe, resistant anxiety, but with significant side effect burden).
• Non-pharmacological Management: CBT, relaxation techniques, mindfulness, exercise, and addressing underlying stressors are critical.

Bipolar Disorder in Older Adults

• Prevalence and Presentation: While less common for new onset in old age, bipolar disorder often continues from earlier life. It can be challenging to diagnose due to overlap with dementia, stroke, and other psychiatric conditions. Mania may present with irritability, agitation, and cognitive disorganization rather than classic euphoria.
• Pharmacological Management:
  • Mood Stabilizers: Lithium (requires careful monitoring of renal function, thyroid function, and drug interactions; narrow therapeutic index, risk of toxicity), valproate (monitor for tremor, cognitive side effects, hepatotoxicity, thrombocytopenia), lamotrigine (for bipolar depression, monitor for rash).
  • Atypical Antipsychotics: Often used for acute mania and maintenance (e.g., quetiapine, olanzapine, risperidone, aripiprazole). Monitor for metabolic side effects, EPS, and QTc prolongation. Olanzapine and risperidone carry a Black Box Warning for increased mortality in elderly patients with dementia-related psychosis.

Differentiating Delirium, Dementia, and Depression

A crucial skill for CGP candidates is distinguishing these "3 Ds," as their symptoms can overlap in older adults:

• Delirium: Acute onset, fluctuating course, disturbed attention, altered consciousness. Often precipitated by an acute illness, medication, or surgery.
  • Pharmacist Role: Identify causative agents (e.g., anticholinergics, benzodiazepines, opioids), recommend discontinuation or dose reduction.
• Dementia: Gradual onset, progressive cognitive decline, typically preserved attention early on, clear consciousness.
• Depression: Subacute onset, often a history of mood disturbance, prominent anhedonia, self-neglect, cognitive complaints (pseudodementia) that improve with antidepressant treatment.

Polypharmacy and Drug-Induced Mood/Anxiety

Older adults are frequently on multiple medications, and many drugs can cause or exacerbate mood and anxiety symptoms. Pharmacists play a vital role in identifying these drug-induced effects. Examples include:

• Depression: Beta-blockers (especially lipophilic ones), corticosteroids, opioids, benzodiazepines, interferon alpha, varenicline, some anticonvulsants, anticholinergics.
• Anxiety/Agitation: Decongestants, bronchodilators, caffeine, thyroid hormones, corticosteroids, anticholinergics, SSRIs (initial activation), stimulants, benzodiazepine withdrawal.

Pharmacokinetic and Pharmacodynamic Changes

Age-related changes significantly impact how older adults respond to psychotropic medications:

• Pharmacokinetics (ADME):
  • Absorption: Generally unchanged.
  • Distribution: Decreased lean body mass, increased body fat, decreased total body water, decreased albumin levels. This can lead to increased volume of distribution for lipophilic drugs and higher free fractions for highly protein-bound drugs.
  • Metabolism: Reduced hepatic blood flow and enzyme activity (especially CYP450) can prolong drug half-lives.
  • Excretion: Decreased renal function is common, impacting drugs primarily cleared by the kidneys.
• Pharmacodynamics: Altered receptor sensitivity (e.g., increased sensitivity to CNS depressants like benzodiazepines, decreased sensitivity to beta-agonists) can lead to exaggerated responses or reduced efficacy.

How It Appears on the Exam

The CGP Certified Geriatric Pharmacist practice questions will test your ability to apply these concepts in realistic clinical scenarios. Expect questions that:

• Present complex patient cases with multiple comorbidities and polypharmacy, requiring you to identify potential drug-induced mood/anxiety symptoms.
• Ask about the most appropriate first-line pharmacotherapy for depression or anxiety, considering age-related changes, comorbidities, and drug interactions.
• Challenge you to identify potentially inappropriate medications according to the Beers Criteria (e.g., long-term benzodiazepine use, TCAs).
• Require you to recommend appropriate dosing adjustments and monitoring parameters for psychotropic medications in older adults.
• Test your knowledge of non-pharmacological interventions and when to recommend them.
• Present scenarios where you must differentiate between delirium, dementia, and depression.
• Assess your understanding of specific adverse effects of psychotropic medications in older adults (e.g., hyponatremia with SSRIs, falls with benzodiazepines).

Study Tips for Mastering This Topic

To effectively prepare for this section of the CGP exam:

• Focus on Guidelines: Review current guidelines for depression and anxiety treatment in older adults (e.g., American Psychiatric Association, AGS Beers Criteria).
• Master the Beers Criteria: Understand which psychotropic medications are potentially inappropriate for older adults and why. This is a high-yield area.
• Understand Pharmacokinetic/Pharmacodynamic Changes: Be able to explain how these changes impact drug selection, dosing, and monitoring for psychotropics.
• Practice Case Studies: Work through scenarios that involve identifying atypical presentations, drug interactions, and appropriate medication adjustments for older adults with mood and anxiety disorders. Utilize free practice questions to solidify your understanding.
• Create Comparison Charts: Develop tables comparing different antidepressant and anxiolytic classes, highlighting their specific risks and benefits in the geriatric population.
• Review Screening Tools: Familiarize yourself with the GDS-15 and GAD-7.
• Identify Drug-Induced Symptoms: Make a list of common medications that can cause or worsen mood and anxiety symptoms.

Common Mistakes to Watch Out For

Avoid these common pitfalls that can lead to incorrect answers on the CGP exam and suboptimal patient care:

• Overlooking Atypical Presentations: Failing to recognize depression or anxiety when classic symptoms are absent, leading to missed diagnoses.
• Misdiagnosing Depression as Dementia: Attributing cognitive complaints solely to dementia without considering reversible causes like depression (pseudodementia).
• Ignoring Non-Pharmacological Interventions: Over-reliance on medication without considering the vital role of psychotherapy, exercise, and social support.
• Failing to Identify Drug-Induced Symptoms: Not performing a thorough medication review to identify drugs contributing to mood or anxiety symptoms.
• Inappropriate Benzodiazepine Use: Recommending or continuing long-term benzodiazepines for anxiety in older adults, despite the known risks and Beers Criteria recommendations.
• Not Adjusting for Age-Related Changes: Prescribing standard adult doses without considering decreased renal/hepatic function or increased drug sensitivity.
• Missing Drug-Drug Interactions: Overlooking critical interactions between psychotropics and other medications commonly used by older adults (e.g., SSRIs and anticoagulants, citalopram and other QTc-prolonging drugs).

Quick Review / Summary

Mood and anxiety disorders are highly prevalent in geriatric patients, presenting unique diagnostic and therapeutic challenges for Certified Geriatric Pharmacists. Key takeaways include:

• Recognize the atypical presentations of depression and anxiety in older adults.
• Prioritize SSRIs/SNRIs as first-line pharmacotherapy, starting low and going slow.
• Exercise extreme caution with benzodiazepines due to significant risks, adhering to Beers Criteria.
• Be vigilant for drug-induced mood and anxiety symptoms.
• Understand and apply knowledge of age-related pharmacokinetic and pharmacodynamic changes to optimize drug selection and dosing.
• Always consider and advocate for non-pharmacological interventions.
• Be proficient in differentiating delirium, dementia, and depression.

Your role as a CGP is critical in optimizing pharmacotherapy, minimizing adverse effects, and improving the mental health and overall well-being of older adults. Mastering these concepts will not only prepare you for the CGP exam but also empower you to make a profound difference in your patients' lives.